Shares in Sanofi (NYSE:SNY) have gained 11% to $44.58 apiece since the company released its 4th-quarter and full year 2016 financial results in February.
The French company posted profits of $731.5 million on sales of $8.21 billion for the 3 months ended Dec. 31, for bottom-line growth of 136.5% on sales growth of 3.3% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were $1.16 (€1.25).
“2016 was a busy year for Sanofi as we progressed on our 2020 strategic roadmap. We successfully closed the Boehringer Ingelheim asset swap, lifting us into a leadership position in consumer healthcare,” president & CEO Olivier Brandicourt said in prepared remarks. “Our streamlined organization started to deliver and supported a stronger financial performance than initially anticipated. At the same time, we completed the filing of our breakthrough innovation Dupixent for the first indication, atopic dermatitis, in the U.S and Europe. Separately, we recently advanced five new molecules into registrational studies.”
For the full year of 2016, Sanofi posted profits of $4.36 billion on sales of $31.31 billion, for bottom-line growth of 9.8% on sales loss of -1%. The company also reported earnings per share of $3.39 (€3.04) .
($1 = €1.08)
Here’s a look at the results from other players in the drug-delivery space:
| Revenue | % y/y | Profits | % y/y | Earnings | % y/y | |
| Roche (PINK:RHHBY) | $50.11 | 4% | $9.80 | 7% | $14.63 | 5% |
| Novartis (NYSE:NVS) | $48.52 | -2% | $11.31 | -6% | $4.75 | -2% |
| Merck (NYSE:MRK) | $39.80 | 0.8% | $5.69 | 28% | $2.04 | 31% |
| GlaxoSmithKline (NYSE:GSK) |
$34.79 | 17% | $2.81 | -75% | $0.23 | -99% |
| Medtronic (NYSE:MDT) |
$28.83 | 42% | $3.54 | 32% | $2.48 | 3% |
| Amgen (NSDQ:AMGN) |
$22.99 | 6% | $7.72 | 11% | $10.24 | 13% |
| Teva (NYSE:TEVA) | $21.90 | 11% | $0.33 | -79% | $0.07 | -96% |
| Eli Lilly (NYSE:LLY) | $21.22 | 6% | $2.74 | 14% | $2.58 | 14% |
| Bristol-Myers Squibb (NYSE:BMY) |
$19.43 | 17% | $4.51 | 176% | $2.65 | 184% |
| Biogen (NSDQ:BIIB) | $11.40 | 6% | $3.70 | 4% | $16.93 | 10% |
| Mylan (NSDQ:MYL) | $11.08 | 18% | $0.48 | -43% | $0.92 | -46% |
| C.R. Bard (NYSE:BCR) | $3.71 | 9% | 0.53 | 292.0% | $7.03 | 297.0% |
| Catalent (NYSE:CTLT) | $1.85 | 6% | $0.11 | -43% | $0.89 | 49% |
| Abbott (NYSE:ABT) | $0.02 | 2% | $1.40 | -68% | $0.71 | -59% |
| *All data for fiscal year 2016 |
||||||
| *In billions, USD | ||||||
